# EDGAR Filing Document

**Accession Number:** 0001875620
**File Stem:** 0001875620-25-000020
**Filing Date:** 2025-8
**Character Count:** 15093
**Document Hash:** 28061cd825f19bb01895afc5aacdf966
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001875620-25-000020.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001875620-25-000020

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acrivon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781174
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825125532
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93824
- **FILM NUMBER:** 251209628

**BUSINESS ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY, SUITE 100
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-207-8979

**MAIL ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY, SUITE 100
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sands Capital Life Sciences Pulse Fund II, L.P.
- **CENTRAL INDEX KEY:** 0001875620

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O SANDS CAPITAL ALTERNATIVES, LLC
- **STREET 2:** 1000 WILSON BOULEVARD, SUITE 3000
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22209
- **BUSINESS PHONE:** 703-562-4000

**MAIL ADDRESS:**
- **STREET 1:** C/O SANDS CAPITAL ALTERNATIVES, LLC
- **STREET 2:** 1000 WILSON BOULEVARD, SUITE 3000
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22209

## Ex-1

------

EXHIBIT 1

to

SCHEDULE 13G

JOINT ACQUISITION STATEMENT

PURSUANT TO SECTION 240.13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: August 13, 2025

---

| |
|:---|
| **Sands Capital Life Sciences Pulse Fund II, L.P.**<br>By: Sands Capital Life Sciences Pulse Fund II-GP, L.P., *its general partner*<br>By: Sands Capital Life Sciences Pulse Fund II-GP, LLC, *its general partner*<br>By: /s/ Jonathan Goodman |
| Name: Jonathan Goodman |
| Title: General Counsel |
| <br> **Sands Capital Alternatives, LLC**<br>|
| By: /s/ Jonathan Goodman |
| Name: Jonathan Goodman<br> Title: General Counsel<br>By: /s/ Frank M. Sands |
| Name: Frank M. Sands |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Issuer:** Acrivon Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** 004890109

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Sands Capital Life Sciences Pulse Fund II, L.P. | Names of Reporting Persons<br>Sands Capital Life Sciences Pulse Fund II, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2122605.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2122605.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).

---

| 1. | Names of Reporting Persons<br>Sands Capital Alternatives, LLC | Names of Reporting Persons<br>Sands Capital Alternatives, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2122605.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2122605.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).

---

| 1. | Names of Reporting Persons<br>SANDS FRANK M. | Names of Reporting Persons<br>SANDS FRANK M. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2122605.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2122605.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2122605.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).

---

**Item 1(a). Name of Issuer:**
Acrivon Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
480 ARSENAL WAY, SUITE 100, 480 ARSENAL WAY, SUITE 100, WATERTOWN, MASSACHUSETTS, 02472.

**Item 2(a). Name of Person Filing:**
This Schedule 13G is being filed jointly by: (i) Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), with respect to the shares of Common Stock held by it; (ii) Sands Capital Alternatives, LLC ("Sands Capital Alternatives"), the investment manager of Sands Pulse Fund II, with respect to the shares of common Stock held by Sands Pulse Fund II; and (iii) Frank M. Sands ("Sands"), with respect to the shares of Common Stock held by Sands Pulse Fund II.  Sands Pulse Fund II, Sands Capital Alternatives and Sands are together referred to herein as the "Reporting Persons".

Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP LP") is the general partner of Sands Pulse Fund II.  Sands Capital Life Sciences Pulse Fund-GP, LLC ("Sands Pulse GP LLC" and, together with Sands Pulse GP LP, the "Sands General Partners") is the general partner of Sands Pulse GP LP.

Sands Capital Alternatives is the investment manager of Sands Pulse Fund II and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II.  Sands holds ultimate voting and investment power over securities held by Sands Pulse Fund II, and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II.  Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein.

**Item 2(b). Address of Principal Business Office:**
The principal business address of each of the Reporting Persons and the Sands General Partners is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.

**Item 2(c). Citizenship:**
Sands Pulse Fund II and Sands Pulse GP LP are organized under the laws of the Cayman Islands. Sands Capital Alternatives and Sands Pulse GP LLC are organized under the laws of Delaware.  Sands is a citizen of the United States.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
004890109

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See rows 5 through 11 of cover pages.

**(b) Percent of class:**

See rows 5 through 11 of cover pages.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See rows 5 through 11 of cover pages.

**(ii) Shared power to vote or to direct the vote:**

See rows 5 through 11 of cover pages.

**(iii) Sole power to dispose or to direct the disposition of:**

See rows 5 through 11 of cover pages.

**(iv) Shared power to dispose or to direct the disposition of:**

See rows 5 through 11 of cover pages.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Sands Capital Life Sciences Pulse Fund II, L.P.**

**Date:** 08/13/2025

**By:** /s/ Jonathan Goodman

**Name & Title:** Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.

**Sands Capital Alternatives, LLC**

**Date:** 08/13/2025

**By:** /s/ Jonathan Goodman

**Name & Title:** Jonathan Goodman, General Counsel

**SANDS FRANK M.**

**Date:** 08/13/2025

**By:** /s/ Frank M. Sands

**Name & Title:** Frank M. Sands